Corlanor

(Ivabradine)

Corlanor

Drug updated on 11/9/2023

Dosage FormTablet (oral; 5 mg, 7.5 mg); Solution (oral; 5 mg/5 mL)
Drug ClassHyperpolarization-activated cyclic nucleotide-gated channel blockers
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.
  • For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Corlanor (ivabradine) Prescribing Information.2021Amgen Inc., Thousand Oaks, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Ivabradine in patients with heart failure: a systematic literature review2023Journal of market access & health policy
Comparative Efficacy of Different Drugs for the Treatment of Dilated Cardiomyopathy: A Systematic Review and Network Meta-analysis2023Drugs in R&D
Meta-Analysis on Drug and Device Therapy of New York Heart Association Functional Class IV Heart Failure With Reduced Ejection Fraction2023The American journal of cardiology
The effect of ivabradine therapy on dilated cardiomyopathy patients with congestive heart failure: a systematic review and meta-analysis2023Frontiers in cardiovascular medicine
Ivabradine and atrial fibrillation: a meta-analysis of randomized controlled trials.2022Journal of Cardiovascular Pharmacology
A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction2022JACC. Heart failure
Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction2022Journal of internal medicine
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis2022European heart journal. Cardiovascular pharmacotherapy
Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis2022Frontiers in cardiovascular medicine
Effectiveness and safety of ivabradine in the treatment of acute myocardial infarction: a systematic review and meta-analysis.2021Annals of Palliative Medicine
Pharmacotherapies in heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.2021Cureus
Pharmacotherapy for heart failure with reduced ejection fraction and health-related quality of life: a systematic review and meta-analysis.2021European Journal of Heart Failure
Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: meta-analysis of randomized controlled trials.2021Clinical Cardiology
Effect of ivabradine on exercise capacity in individuals with heart failure with preserved ejection fraction.2021Heart Failure Reviews
Effect of ivabradine in heart failure: a meta-analysis of heart failure patients with reduced versus preserved ejection fraction2021Canadian journal of physiology and pharmacology
Effect of ivabradine on major adverse cardiovascular events and mortality in critically ill patients: a systematic review and meta-analyses of randomised controlled trials with trial sequential analyses.2020British Journal of Anaesthesia
New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF): A Bayesian network meta-analysis2020Medicine
Effects of Ivabradine on Cardiac Remodeling in Patients With Stable Symptomatic Heart Failure: A Systematic Review and Meta-analysis2020Clinical therapeutics
Effect of Ivabradine on Left Ventricular Diastolic Function, Exercise Tolerance and Quality of Life in Patients With Heart Failure: A Systemic Review and Meta-Analysis of Randomized Controlled Trials2020Cardiology research
Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure2019International heart journal
The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis.2018International Journal of Clinical Pharmacy
The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis2018International Journal of Clinical Pharmacy
Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis2018European journal of heart failure

Clinical Practice Guidelines